Product
XBB-1-5 Vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve ParticipantsStatus: Active (not recruiting), Estimated PCD: 2023-11-15